Loading
For rare cancers there is often no genetic clue and no trial to join. Testing drugs directly on the patient's fresh tumour cells has guided treatment with reported benefit in a randomised haematology study and in paediatric case series; turnaround and tissue quality are the barriers.
Functional precision medicine, ex vivo drug sensitivity testing on fresh patient material, guided treatment with reported benefit in a randomised haematology study and in paediatric and rare solid tumour case series. Turnaround, tissue quality and the absence of standardised reporting are the barriers. For rare cancers where genomics is uninformative, function is the only remaining evidence source.
Shares Champions Oncology, Xilis, Patient-derived xenografts, Functional (ex vivo) drug testing.
Shares Curesponse, SEngine Precision Medicine, Xilis, Functional (ex vivo) drug testing.
Shares Rare cancers are not so rare: the rare cancer burden in Europe, Patient-derived xenografts, Functional (ex vivo) drug testing, Patient-derived organoids.
Shares Curesponse, SEngine Precision Medicine, Xilis, Patient-derived xenografts.
Shares Curesponse, SEngine Precision Medicine, Xilis, Functional (ex vivo) drug testing.
Shares Patient-derived xenografts, Patient-derived organoids, Lab models that fail to predict what happens in patients, Rare and paediatric cancers without markets.
Shares Curesponse, Functional (ex vivo) drug testing, Patient-derived organoids, Lab models that fail to predict what happens in patients.
Shares Champions Oncology, Patient-derived xenografts, Lab models that fail to predict what happens in patients.